1. Home
  2. VRTX vs BSX Comparison

VRTX vs BSX Comparison

Compare VRTX & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$457.11

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo Boston Scientific Corporation

BSX

Boston Scientific Corporation

HOLD

Current Price

$96.46

Market Cap

137.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
BSX
Founded
1989
1979
Country
United States
United States
Employees
6100
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
137.8B
IPO Year
1991
1992

Fundamental Metrics

Financial Performance
Metric
VRTX
BSX
Price
$457.11
$96.46
Analyst Decision
Buy
Strong Buy
Analyst Count
25
17
Target Price
$494.64
$125.88
AVG Volume (30 Days)
1.6M
10.8M
Earning Date
02-09-2026
02-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.68
EPS
14.22
1.87
Revenue
$11,723,300,000.00
$19,349,000,000.00
Revenue This Year
$11.01
$21.05
Revenue Next Year
$8.74
$11.43
P/E Ratio
$32.08
$51.13
Revenue Growth
10.33
21.61
52 Week Low
$362.50
$85.98
52 Week High
$519.68
$109.50

Technical Indicators

Market Signals
Indicator
VRTX
BSX
Relative Strength Index (RSI) 61.34 49.71
Support Level $445.41 $90.42
Resistance Level $459.05 $97.27
Average True Range (ATR) 10.50 2.17
MACD 0.26 0.25
Stochastic Oscillator 83.14 67.66

Price Performance

Historical Comparison
VRTX
BSX

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About BSX Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Share on Social Networks: